{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:12:49Z","timestamp":1789009969427,"version":"build-2803163510"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82350710226"],"award-info":[{"award-number":["82350710226"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370178"],"award-info":[{"award-number":["82370178"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100021171","name":"Guangdong Basic and Applied Basic Research Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-025-01370-1","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T15:36:58Z","timestamp":1761320218000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Identification of specific T-cell response and T-cell receptor targeting shared neoantigen for acute myeloid leukemia"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0137-7382","authenticated-orcid":false,"given":"Weijun","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyi","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwen","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anqin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7198-2134","authenticated-orcid":false,"given":"Kankan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,24]]},"reference":[{"key":"1370_CR1","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/S0140-6736(18)31041-9","volume":"392","author":"NJ Short","year":"2018","unstructured":"Short NJ, Rytting ME, Cortes JE. Acute myeloid leukaemia. Lancet. 2018;392:593\u2013606.","journal-title":"Lancet"},{"key":"1370_CR2","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H Dohner","year":"2015","unstructured":"Dohner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373:1136\u201352.","journal-title":"N Engl J Med"},{"key":"1370_CR3","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1200\/JCO.2005.06.027","volume":"23","author":"DA Breems","year":"2005","unstructured":"Breems DA, Van Putten WL, Huijgens PC, Ossenkoppele GJ, Verhoef GE, Verdonck LF, et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol. 2005;23:1969\u201378.","journal-title":"J Clin Oncol"},{"key":"1370_CR4","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/ajh.23858","volume":"90","author":"N Pemmaraju","year":"2015","unstructured":"Pemmaraju N, Kantarjian H, Garcia-Manero G, Pierce S, Cardenas-Turanzas M, Cortes J, et al. Improving outcomes for patients with acute myeloid leukemia in first relapse: a single-center experience. Am J Hematol. 2015;90:27\u201330.","journal-title":"Am J Hematol"},{"key":"1370_CR5","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/nature10738","volume":"481","author":"L Ding","year":"2012","unstructured":"Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, Welch JS, et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature. 2012;481:506\u201310.","journal-title":"Nature"},{"key":"1370_CR6","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1182\/blood-2013-01-479188","volume":"122","author":"J Kronke","year":"2013","unstructured":"Kronke J, Bullinger L, Teleanu V, Tschurtz F, Gaidzik VI, Kuhn MW, et al. Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia. Blood. 2013;122:100\u20138.","journal-title":"Blood"},{"key":"1370_CR7","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1046\/j.1365-2141.1999.01256.x","volume":"104","author":"Y Nakano","year":"1999","unstructured":"Nakano Y, Kiyoi H, Miyawaki S, Asou N, Ohno R, Saito H, et al. Molecular evolution of acute myeloid leukaemia in relapse: unstable N-ras and FLT3 genes compared with p53 gene. Br J Haematol. 1999;104:659\u201364.","journal-title":"Br J Haematol"},{"key":"1370_CR8","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","volume":"368","author":"TJ Ley","year":"2013","unstructured":"Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, Robertson A, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368:2059\u201374.","journal-title":"N Engl J Med"},{"key":"1370_CR9","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/nature12634","volume":"502","author":"C Kandoth","year":"2013","unstructured":"Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, et al. Mutational landscape and significance across 12 major cancer types. Nature. 2013;502:333\u20139.","journal-title":"Nature"},{"key":"1370_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2021.100905","volume":"52","author":"JC Zhao","year":"2022","unstructured":"Zhao JC, Agarwal S, Ahmad H, Amin K, Bewersdorf JP, Zeidan AM. A review of FLT3 inhibitors in acute myeloid leukemia. Blood Rev. 2022;52:100905.","journal-title":"Blood Rev"},{"key":"1370_CR11","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","volume":"378","author":"CD DiNardo","year":"2018","unstructured":"DiNardo CD, Stein EM, de Botton S, Roboz GJ, Altman JK, Mims AS, et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med. 2018;378:2386\u201398.","journal-title":"N Engl J Med"},{"key":"1370_CR12","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.aaa4971","volume":"348","author":"TN Schumacher","year":"2015","unstructured":"Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015;348:69\u201374.","journal-title":"Science"},{"key":"1370_CR13","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1056\/NEJMoa2119662","volume":"386","author":"R Leidner","year":"2022","unstructured":"Leidner R, Sanjuan SN, Huang H, Sprott D, Zheng C, Shih YP, et al. Neoantigen T-cell receptor gene therapy in pancreatic cancer. N Engl J Med. 2022;386:2112\u20139.","journal-title":"N Engl J Med"},{"key":"1370_CR14","doi-asserted-by":"publisher","first-page":"2985","DOI":"10.1182\/blood-2006-07-032839","volume":"109","author":"C Graf","year":"2007","unstructured":"Graf C, Heidel F, Tenzer S, Radsak MP, Solem FK, Britten CM, et al. A neoepitope generated by an FLT3 internal tandem duplication (FLT3-ITD) is recognized by leukemia-reactive autologous CD8+ T cells. Blood. 2007;109:2985\u20138.","journal-title":"Blood"},{"key":"1370_CR15","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1182\/blood.2023021979","volume":"143","author":"WK Leung","year":"2024","unstructured":"Leung WK, Torres CA, French-Kim M, Shafer P, Mamonkin M, Hill LC, et al. Targeting IDH2R140Q and other neoantigens in acute myeloid leukemia. Blood. 2024;143:1726\u201337.","journal-title":"Blood"},{"key":"1370_CR16","doi-asserted-by":"publisher","first-page":"3310","DOI":"10.1093\/bioinformatics\/btu548","volume":"30","author":"A Szolek","year":"2014","unstructured":"Szolek A, Schubert B, Mohr C, Sturm M, Feldhahn M, Kohlbacher O. OptiType: precision HLA typing from next-generation sequencing data. Bioinformatics. 2014;30:3310\u20136.","journal-title":"Bioinformatics"},{"key":"1370_CR17","doi-asserted-by":"publisher","first-page":"W449","DOI":"10.1093\/nar\/gkaa379","volume":"48","author":"B Reynisson","year":"2020","unstructured":"Reynisson B, Alvarez B, Paul S, Peters B, Nielsen M. NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data. Nucleic Acids Res. 2020;48:W449\u2013W454.","journal-title":"Nucleic Acids Res"},{"key":"1370_CR18","doi-asserted-by":"publisher","first-page":"21443","DOI":"10.1074\/jbc.M010791200","volume":"276","author":"AK Sharma","year":"2001","unstructured":"Sharma AK, Kuhns JJ, Yan S, Friedline RH, Long B, Tisch R, et al. Class I major histocompatibility complex anchor substitutions alter the conformation of T cell receptor contacts. J Biol Chem. 2001;276:21443\u20139.","journal-title":"J Biol Chem"},{"key":"1370_CR19","doi-asserted-by":"publisher","first-page":"5121","DOI":"10.1093\/bioinformatics\/btz459","volume":"35","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Sanner MF. AutoDock CrankPep: combining folding and docking to predict protein-peptide complexes. Bioinformatics. 2019;35:5121\u20137.","journal-title":"Bioinformatics"},{"key":"1370_CR20","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1002\/jcc.20291","volume":"26","author":"D Van Der Spoel","year":"2005","unstructured":"Van Der Spoel D, Lindahl E, Hess B, Groenhof G, Mark AE, Berendsen HJ. GROMACS: fast, flexible, and free. J Comput Chem. 2005;26:1701\u201318.","journal-title":"J Comput Chem"},{"key":"1370_CR21","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s00262-014-1631-y","volume":"64","author":"Y Li","year":"2015","unstructured":"Li Y, Zhou W, Du J, Jiang C, Xie X, Xue T, et al. Generation of cytotoxic T lymphocytes specific for native or modified peptides derived from the epidermal growth factor receptor pathway substrate 8 antigen. Cancer Immunol Immunother. 2015;64:259\u201369.","journal-title":"Cancer Immunol Immunother"},{"key":"1370_CR22","doi-asserted-by":"publisher","first-page":"5357","DOI":"10.1158\/1078-0432.CCR-18-0142","volume":"24","author":"T Matsuda","year":"2018","unstructured":"Matsuda T, Leisegang M, Park JH, Ren L, Kato T, Ikeda Y, et al. Induction of neoantigen-specific cytotoxic T cells and construction of t-cell receptor-engineered t cells for ovarian cancer. Clin Cancer Res. 2018;24:5357\u201367.","journal-title":"Clin Cancer Res"},{"key":"1370_CR23","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1126\/science.aaa3828","volume":"348","author":"BM Carreno","year":"2015","unstructured":"Carreno BM, Magrini V, Becker-Hapak M, Kaabinejadian S, Hundal J, Petti AA, et al. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science. 2015;348:803\u20138.","journal-title":"Science"},{"key":"1370_CR24","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/s41586-018-0810-y","volume":"565","author":"N Hilf","year":"2019","unstructured":"Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanovic S, Gouttefangeas C, et al. Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature. 2019;565:240\u20135.","journal-title":"Nature"},{"key":"1370_CR25","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1172\/JCI97482","volume":"129","author":"DI van der Lee","year":"2019","unstructured":"van der Lee DI, Reijmers RM, Honders MW, Hagedoorn RS, de Jong RC, Kester MG, et al. Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia. J Clin Investig. 2019;129:774\u201385.","journal-title":"J Clin Investig"},{"key":"1370_CR26","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1182\/blood.V81.5.1369.1369","volume":"81","author":"C Gambacorti-Passerini","year":"1993","unstructured":"Gambacorti-Passerini C, Grignani F, Arienti F, Pandolfi PP, Pelicci PG, Parmiani G. Human CD4 lymphocytes specifically recognize a peptide representing the fusion region of the hybrid protein pml\/RAR alpha present in acute promyelocytic leukemia cells. Blood. 1993;81:1369\u201375.","journal-title":"Blood"},{"key":"1370_CR27","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s40164-022-00353-3","volume":"11","author":"W Zhou","year":"2022","unstructured":"Zhou W, Yu J, Li Y, Wang K. Neoantigen-specific TCR-T cell-based immunotherapy for acute myeloid leukemia. Exp Hematol Oncol. 2022;11:100.","journal-title":"Exp Hematol Oncol"},{"key":"1370_CR28","doi-asserted-by":"publisher","first-page":"5127","DOI":"10.1172\/JCI137723","volume":"130","author":"MA Biernacki","year":"2020","unstructured":"Biernacki MA, Foster KA, Woodward KB, Coon ME, Cummings C, Cunningham TM, et al. CBFB-MYH11 fusion neoantigen enables T cell recognition and killing of acute myeloid leukemia. J Clin Investig. 2020;130:5127\u201341.","journal-title":"J Clin Investig"},{"key":"1370_CR29","doi-asserted-by":"publisher","first-page":"6325","DOI":"10.1172\/JCI140378","volume":"130","author":"S Mueller","year":"2020","unstructured":"Mueller S, Taitt JM, Villanueva-Meyer JE, Bonner ER, Nejo T, Lulla RR, et al. Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma. J Clin Investig. 2020;130:6325\u201337.","journal-title":"J Clin Investig"},{"key":"1370_CR30","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1038\/s41375-021-01232-2","volume":"35","author":"FP Tambaro","year":"2021","unstructured":"Tambaro FP, Singh H, Jones E, Rytting M, Mahadeo KM, Thompson P, et al. Autologous CD33-CAR-T cells for treatment of relapsed\/refractory acute myelogenous leukemia. Leukemia. 2021;35:3282\u20136.","journal-title":"Leukemia"},{"key":"1370_CR31","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1182\/blood-2011-11-394395","volume":"120","author":"J Greiner","year":"2012","unstructured":"Greiner J, Ono Y, Hofmann S, Schmitt A, Mehring E, Gotz M, et al. Mutated regions of nucleophosmin 1 elicit both CD4(+) and CD8(+) T-cell responses in patients with acute myeloid leukemia. Blood. 2012;120:1282\u20139.","journal-title":"Blood"},{"key":"1370_CR32","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41551-020-00625-5","volume":"5","author":"G Xie","year":"2021","unstructured":"Xie G, Ivica NA, Jia B, Li Y, Dong H, Liang Y, et al. CAR-T cells targeting a nucleophosmin neoepitope exhibit potent specific activity in mouse models of acute myeloid leukaemia. Nat Biomed Eng. 2021;5:399\u2013413.","journal-title":"Nat Biomed Eng"},{"key":"1370_CR33","doi-asserted-by":"publisher","first-page":"2390","DOI":"10.1038\/leu.2015.165","volume":"29","author":"CC Smith","year":"2015","unstructured":"Smith CC, Lin K, Stecula A, Sali A, Shah NP. FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors. Leukemia. 2015;29:2390\u20132.","journal-title":"Leukemia"},{"key":"1370_CR34","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1038\/s43018-023-00642-8","volume":"4","author":"E Giannakopoulou","year":"2023","unstructured":"Giannakopoulou E, Lehander M, Virding CS, Yang W, Li Y, Karpanen T, et al. A T cell receptor targeting a recurrent driver mutation in FLT3 mediates elimination of primary human acute myeloid leukemia in vivo. Nat Cancer. 2023;4:1474\u201390.","journal-title":"Nat Cancer"},{"key":"1370_CR35","doi-asserted-by":"crossref","unstructured":"Lu YC, Zheng Z, Lowery FJ, Gartner JJ, Prickett TD, Robbins PF, et al. Direct identification of neoantigen-specific TCRs from tumor specimens by high-throughput single-cell sequencing. J Immunother Cancer. 2021;9.","DOI":"10.1136\/jitc-2021-002595"},{"key":"1370_CR36","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/s42256-021-00383-2","volume":"3","author":"T Lu","year":"2021","unstructured":"Lu T, Zhang Z, Zhu J, Wang Y, Jiang P, Xiao X, et al. Deep learning-based prediction of the T cell receptor-antigen binding specificity. Nat Mach Intell. 2021;3:864\u201375.","journal-title":"Nat Mach Intell"},{"key":"1370_CR37","doi-asserted-by":"crossref","unstructured":"Zhou W, Xiang W, Yu J, Ruan Z, Pan Y, Wang K, et al. NeoTCR: an immunoinformatic database of experimentally-supported functional neoantigen-specific TCR sequences. Genom Proteom Bioinform. 2024.","DOI":"10.1101\/2023.02.13.528383"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01370-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01370-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01370-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T15:37:03Z","timestamp":1761320223000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01370-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,24]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1370"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01370-1","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,24]]},"assertion":[{"value":"22 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have declared no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Ethics Committee of Ruijin Hospital (2020-413). Materials from patients and healthy donors were collected after written informed consent according to the Declaration of Helsinki. Animal experiments were conducted in accordance with institutional guidelines after obtaining permission from the Animal Ethics Committee of Ruijin Hospital (RJ2023064).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"178"}}